Home Cart Sign in  
Chemical Structure| 23491-52-3 Chemical Structure| 23491-52-3
Chemical Structure| 23491-52-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hoechst 33342, a marker dye in the Hoechst series, serves as a live nuclear marker dye. It binds to the grooves in the DNA double strand, particularly favoring the A/T-rich DNA strand. Although it binds to all nucleic acids, its fluorescence intensity significantly increases with A/T-rich double strand DNA, making it suitable for labeling living cells. The fluorescence intensity of Hoechst dye rises with an increase in the solution's pH.

Synonyms: HOE 33342; bisBenzimide H 33342; Bisbenzimide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Ma, Xiaoxia ; Cao, Di ; Zhang, Yan ; Ding, Xiaoyun ; Hu, Zhiqiang ; Wang, Jing

Abstract: Triple-negative breast cancer (TNBC) is highly heterogeneous, often leading to resistance to chemotherapy agents like paclitaxel (PTX) and resulting in suboptimal outcomes. The anti-angiogenic agent apatinib not only enhances chemotherapy sensitivity but also involves in regulating ferroptosis. However, the potential of combining apatinib with PTX to improve treatment efficacy in refractory TNBC by increasing tumor cell susceptibility to ferroptosis remains elusive. This study aims to elucidate whether inducing ferroptosis participates in the beneficial effects of apatinib combined with PTX to synergistically suppress TNBC. Herein, we demonstrated that the coadministration of apatinib and PTX exerted significant inhibitory effects on both primary tumor progression and distant metastases to pulmonary and hepatic tissues in TNBC-bearing murine models. Transcriptomic and proteomic analyses indicated that ferroptosis induction is a key mechanism by which the drug combination suppresses TNBC, as evidenced by a marked downregulation of SLC7A11, GPX4, NRF2, and FTH1, and a significant upregulation of ACSL4. In vitro, the combination of 5 μM apatinib and 8 nM PTX synergistically inhibited tumor cell proliferation, migration, and invasion. Notably, the combination therapy markedly augmented ferroptosis in tumor cells through the regulation of the SLC7A11/GPX4/ACSL4 axis, leading to increased intracellular iron accumulation and lipid peroxide generation, concomitant with a reduction in GSH levels. The effect of apatinib combined with PTX on enhancing ferroptosis susceptibility could be exploited as a combination treatment regimen for future TNBC therapy.

Keywords: Apatinib ; Paclitaxel ; Ferroptosis ; GPX4 ; TNBC

Purchased from AmBeed: ; ;

Alternative Products

Product Details of Hoechst 33342

CAS No. :23491-52-3
Formula : C27H28N6O
M.W : 452.55
SMILES Code : CN1CCN(C2=CC=C3NC(C4=CC=C5NC(C6=CC=C(OCC)C=C6)=NC5=C4)=NC3=C2)CC1
Synonyms :
HOE 33342; bisBenzimide H 33342; Bisbenzimide
MDL No. :MFCD00166996
InChI Key :PRDFBSVERLRRMY-UHFFFAOYSA-N
Pubchem ID :1464

Safety of Hoechst 33342

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338
 

Historical Records

Categories